UnitedHealth Group (NYSE: UNH) faces April 21 earnings test after CMS win

UnitedHealth Group is the largest health insurer in the United States by revenue, a company so deeply embedded in American healthcare that it touches pharmacy counters, physician offices, and hospital billing systems simultaneously. After one of the most turbulent years in the company’s four-decade history, UNH shares have fallen roughly 45% from their 52-week high of USD 606.36 to trade around USD 280. On April 7, a significant regulatory tailwind arrived when the Centers for Medicare and Medicaid Services finalised a 2.48% average payment increase for Medicare Advantage plans in 2027, far exceeding the near-flat 0.09% proposal issued in January. The stock surged roughly 10% in after-hours trading. Now the next major test arrives on April 21, when CEO Stephen Hemsley reports Q1 2026 earnings for the first time since returning to the role.

What does UnitedHealth Group actually do, and why is its integrated model so unusual among large-cap healthcare stocks?

UnitedHealth Group operates through two principal platforms. UnitedHealthcare is the insurance arm, providing health coverage to roughly 50 million people across employer, individual, Medicare, and Medicaid markets. It is the largest private health insurer in the United States. Optum is the second platform and the one that makes UnitedHealth genuinely unlike its traditional insurance peers. Optum encompasses three businesses: Optum Health, which owns or is affiliated with approximately 90,000 physicians and operates care delivery sites across the country; Optum Rx, one of the largest pharmacy benefit managers in the United States; and Optum Insight, which sells analytics, software, and advisory services to hospitals, health plans, and government entities.

The logic of this structure is straightforward in theory. By owning the insurer, the doctor’s office, the pharmacy benefit manager, and the data analytics layer, UnitedHealth can theoretically align financial incentives across the care journey in ways pure-play insurers cannot. When a UnitedHealthcare member sees an Optum physician, is prescribed medication through Optum Rx, and has their claim processed using Optum Insight software, the company captures value at every step. This model generated revenues of USD 447.6 billion in 2025, making UnitedHealth one of the largest companies in the world by revenue, ranked seventh on the Fortune Global 500.

The integration that drives UnitedHealth’s revenue also generates its most significant regulatory risk. The Department of Justice has been investigating whether the relationship between UnitedHealthcare and Optum creates anticompetitive conditions for patients, providers, and rival insurers. That investigation remains active and unresolved, and it sits as a persistent overhang above any recovery thesis.

Why did UNH fall nearly 45% in a year, and what combination of factors broke the investment case?

The decline from above USD 600 to near USD 234 at the 52-week low reflects a cascade of simultaneous pressures rather than a single event. The most important structural problem was the medical care ratio, the share of premiums spent on medical claims. In 2024, UnitedHealth’s adjusted medical care ratio was 85.5%. By 2025, it had risen to 88.9%, a 340 basis point deterioration that compressed the operating margin in UnitedHealthcare from 5.2% in 2024 to 2.7% in 2025. The driving forces included higher-than-expected utilisation in Medicare Advantage, funding reductions from the Biden-era Medicare rate cycle, and the downstream effects of the Inflation Reduction Act on Part D pharmacy benefits.

Compounding the operational deterioration was the February 2024 cyberattack on Change Healthcare, UnitedHealth’s claims processing subsidiary. The breach disrupted billing systems across thousands of healthcare providers nationwide and ultimately cost UnitedHealth USD 799 million in direct remediation costs, included in a USD 2.88 billion charge recognised in Q4 2025. The company also replaced CEO Andrew Witty with former CEO Stephen Hemsley in mid-2025, a leadership change that signalled to investors that a deeper reset was underway rather than a cyclical correction.

Then in December 2024, UnitedHealthcare CEO Brian Thompson was shot and killed in New York City, an event that unleashed a wave of public anger about insurance claim denials and thrust the company into an intensely hostile media and political environment at the worst possible time. Taken together, these events compressed the stock by a degree rarely seen in a company of this scale.

What does the CMS Medicare Advantage rate decision mean for UNH investors watching the recovery thesis?

The April 6 finalisation of a 2.48% average payment rate increase for 2027 Medicare Advantage was the single most important regulatory event of the year for managed care investors, and it landed in UnitedHealth’s favour. The gap between the January proposal of 0.09% and the final figure of 2.48% was unusually wide. When accounting for estimated risk score trends, CMS characterised the effective increase as closer to 4.98%. The decision adds over USD 13 billion in aggregate payments to Medicare Advantage plans in 2027.

For UnitedHealth specifically, Medicare Advantage is a core revenue engine. UnitedHealthcare’s Medicare and Retirement segment generated USD 171.3 billion in revenues in 2025, up 23% year-on-year, driven partly by Inflation Reduction Act Part D changes and growth in people served. A higher reimbursement rate for 2027 improves the economics of plan bidding that occurs over the coming months, allows UnitedHealth to compete more aggressively on benefits, and reduces the probability of further membership exits in that segment.

The pattern is also reassuring in itself. For the 2026 rate year, CMS proposed a 2.2% increase before finalising a 5.06% increase. Mizuho health-care specialist Jared Holz noted the 2027 outcome was clearly better than the January proposal and could help companies expand margins in 2027 if expense management continued. William Blair analyst Ryan Daniels observed that the decision to retain the 2024 risk adjustment model rather than adopting the proposed 2027 model was a meaningful concession to industry participants, improving plan revenue visibility and easing concerns tied to earlier policy proposals.

What is at stake in the April 21 Q1 2026 earnings report, and which metrics will move the stock?

The Q1 2026 earnings release on April 21 is the first report delivered by Stephen Hemsley as CEO following his return, and the first quarter where the restructuring charges and cyberattack costs are fully behind the business. That makes it a structurally important moment. Management guided for full-year 2026 adjusted earnings per share of more than USD 17.75, representing at least 8.6% growth over the 2025 adjusted figure of USD 16.35. Consensus estimates for Q1 2026 sit near USD 6.65 adjusted EPS, down approximately 8% from the prior year. Revenue is expected around USD 109.6 billion.

The metric that matters most is the medical care ratio. Management targeted 88.8% plus or minus 50 basis points for full-year 2026. The comparison quarter in Q1 2025 had an MCR of 84.8%, which creates a relatively easy baseline. If the Q1 2026 MCR comes in materially worse than that, the full-year target becomes difficult to defend. The CFO also flagged that approximately two-thirds of 2026 earnings are expected to land in the first half of the year, driven by Part D benefit dynamics and business mix. That front-loading makes Q1 disproportionately important for the full-year narrative.

Membership contraction in Medicare Advantage is also a key watch. Management guided for a planned exit of 2.3 to 2.8 million members from unprofitable contracts, bringing UnitedHealthcare total enrollment to 46.9 to 47.5 million. The Q1 report will show whether that exit is proceeding in an orderly fashion. Optum Health, where operating earnings collapsed from USD 7.8 billion in 2024 to negative USD 278 million in 2025, needs to show early signs of recovery. Management targeted roughly 9% operating earnings growth at Optum Health in 2026. Options traders are pricing in a move of approximately 9% in either direction after the results, reflecting the binary quality of the moment.

How is the market currently pricing UNH relative to its historical valuation and what do analyst targets imply?

At a price near USD 280, UNH trades at a trailing price-to-earnings ratio of approximately 21 times. That is close to the healthcare industry average and significantly below the implied long-run multiple embedded in analyst price targets. Consensus analyst targets sit near USD 357, implying upside of approximately 27% from recent levels. The 52-week range of USD 234.60 to USD 606.36 captures the full extent of the dislocation; at the 52-week high, the company was valued at roughly USD 560 billion. The current market capitalisation near USD 255 billion represents a loss of over USD 300 billion in market value since that peak.

The 3.14% dividend yield, at current prices, is the highest UNH has offered in more than a decade. The company pays USD 8.84 per share annually. Management committed to returning to historical capital deployment practices in the second half of 2026, including buybacks, suggesting confidence in the free cash flow trajectory. Full-year 2026 guidance targets at least USD 18 billion in operating cash flow. Morningstar carries a fair value estimate of USD 197 per share with high uncertainty, while most sell-side consensus targets sit well above the current price. The divergence between the more conservative fundamental valuation and the broadly bullish analyst consensus reflects genuine uncertainty about the resolution timeline for both the DOJ investigations and the Medicare Advantage margin recovery.

What risks does the DOJ investigation create for UNH shareholders over the next 12 to 18 months?

The Department of Justice is simultaneously pursuing criminal and civil investigations into UnitedHealth’s Medicare billing practices and conducting an antitrust review of Optum’s acquisition of physician groups. The criminal investigation centres on whether the company used clinical visits to document diagnoses that inflated Medicare Advantage risk scores and thereby increased federal payments. The antitrust probe examines whether the relationship between UnitedHealthcare and Optum discriminated against rival insurers and independent physician groups in contracting.

UnitedHealth has stated it has full confidence in its practices, that it is cooperating with the Department throughout the process, and that an independent court-appointed special master found no evidence of wrongdoing in a decade-long prior civil challenge related to Medicare Advantage. No charges have been filed. However, the investigation has expanded from its initial scope to include Optum Rx billing practices and physician reimbursement. RBC Capital Markets analyst Ben Hendrix characterised the probe as an incremental overhang, unlikely to produce material financial headwinds in the near term, given the typical timeline of such investigations.

The range of possible outcomes is wide. A negotiated settlement involving operational changes and penalties would be manageable at UnitedHealth’s revenue scale. A structural remedy requiring divestitures of Optum assets would strike at the core of the investment thesis, which is built on the integrated model. Investors should treat the DOJ timeline as genuinely uncertain; the investigation has been ongoing since early 2024 and has not accelerated noticeably under the current administration.

What is the retail investor community saying about UNH, and what is the contrarian bull case at USD 280?

Retail investor interest in UNH has spiked sharply since the stock’s collapse from its highs. Discussion on forums and social platforms centres on two competing narratives. The bear case holds that the integrated model faces structural legal risk, that medical cost inflation is not yet contained, and that the stock is cheap relative to history but not relative to current earnings power. Commentators on TradingView have flagged the USD 300 to USD 305 range as a key resistance zone where institutional sellers have appeared repeatedly.

The bull case, which appears to have gained traction following the April 6 CMS announcement, is that UNH at roughly 20 times earnings with a 3% dividend yield and a new CEO represents a generational entry point in a company with demonstrated pricing power, more than USD 19 billion in operating cash flow, and a healthcare services business that is largely insulated from macro conditions. The recent entry of UNH into the top ten holdings of the Schwab U.S. Dividend Equity ETF, driven by the elevated yield at current prices, has added institutional dividend investors to the shareholder base at these levels.

The most honest framing is that UNH at USD 280 is a recovery bet with material upside if the operational reset holds and legal risk stays contained, and a fundamentally broken thesis if either fails.

Key takeaways for retail investors watching UNH: catalyst timeline, valuation, and the risks that could derail the recovery

• UnitedHealth Group (NYSE: UNH) trades near USD 280, down approximately 45% from its 52-week high of USD 606.36, with a market capitalisation of roughly USD 255 billion and a dividend yield of 3.14%.
• CMS finalised a 2.48% average payment increase for 2027 Medicare Advantage on April 6, significantly above the 0.09% proposed in January and adding more than USD 13 billion in payments to plans, triggering a near 10% after-hours surge in UNH shares.
• Q1 2026 earnings on April 21 are the most important near-term catalyst: options markets are pricing approximately 9% movement in either direction, and the medical care ratio and Optum Health earnings trajectory are the two metrics that will define the full-year recovery narrative.
• Management guided for full-year 2026 adjusted EPS of more than USD 17.75 and operating cash flow of at least USD 18 billion, with roughly two-thirds of earnings expected in the first half.
• Optum Health’s operating earnings collapsed from USD 7.8 billion in 2024 to negative USD 278 million in 2025, making the segment’s recovery the central test of the Hemsley-led restructuring.
• The DOJ is simultaneously investigating Medicare billing practices and Optum’s vertical integration for potential antitrust violations; no charges have been filed, but the timeline and scope of the investigation remain unresolved.
• Consensus analyst price targets near USD 357 imply roughly 27% upside from current levels, but the range of outcomes is wide and the thesis is binary around the dual catalysts of legal resolution and operational recovery.